Category Archives: Immunotherapy

Alternative Cancer Treatment, Cancer Research, Immunotherapy

Immunotherapy Arises as the Closest Thing to Cure for Cancer Yet

The Cure is Coming
The Cure is Coming

For decades, the cure for cancer has been the holy grail of medical research. While there have been significant advances in treatment, an actual cure remains elusive. Thanks to its innovative approach, integrative immunotherapy has emerged as the closest thing to a cure for cancer.

What’s the difference between immunotherapy and conventional treatments?

Traditional chemotherapy can be effective, but it kills healthy cells along with cancer cells, leaving the door open for the disease to return. Immunotherapy is unique in that it trains the body’s own immune system to recognize and fight cancer cells, much as they do with a common cold.

James Larkin is a consultant at London’s Royal Marsden, the leading cancer hospital in the world. He explains that cancer can become resistant to conventional drugs, while immunotherapy works from the inside to boost the body’s natural resources. The idea is that the immune system is “programmed” to change in response to a tumor’s evolution.

A real-life success

Sandra Sayce is a living example of the benefits of integrative immunotherapy. The 52-year-old was originally treated for melanoma in 2001, when lesions were discovered on her lower leg. After the disease returned in 2005 and was diagnosed as stage four, she participated in a trial for an immunotherapy drug called ipilimumab. With no further treatment, the tumors disappeared and she has been cancer-free for nearly 10 years.

Issels® has long been at the forefront of the movement toward integrative immunotherapy. Our programs are individually designed to meet each patient’s specific needs. Visit our website for testimonials from the many people who have been successfully treated with our non-toxic protocols.

Breast Cancer, Cancer Research, Immuno-Oncology, Immunotherapy, News

In 21 States Cancer Tops the List as the Cause of Death

We Haven't Defeated Cancer Yet
We Haven’t Defeated Cancer Yet

Thanks to increasingly successful developments in treatment, such as the state-of-the-art programs at our Issels immuno-oncology clinics, the number of cancer deaths has dropped significantly over the past 20 years. Sadly, though, it has become the leading cause of death in 21 states, emphasizing the need for continuing urgency in research.

Cancer by the numbers

Projections recently released by the American Cancer Society reveal that more than 1.68 million people will be diagnosed with the disease in the upcoming year, while nearly 600,000 will die from it. In terms of overall numbers, 23 percent of deaths are a result of cancer, second only to 24 percent from heart disease.

While lung cancer is still the most deadly form, the 23 percent drop in cancer death rates between 1991 and 2012 is largely due to a steep reduction in smoking. Only 16.8 percent of Americans are smokers, compared to just fewer than 21 percent in 2009.

Continued optimism in the search for a cure

The American Society for Clinical Oncology issued a statement hailing “our nation’s investment in cancer research,” which has led to major breakthroughs in effective treatment. In particular, advancements in innovative programs such as immunotherapy and molecular targeted treatments have led to a consistent decline in death rates from the four major types: lung, breast, prostate and colon/rectum.

For years, our Issels immuno-oncology clinic has been a leader in the use of non-toxic immunotherapy protocols. Visit our website for more information about our programs as well as testimonials from the many patients of all ages who have been helped by our personalized treatment programs.

Alternative Cancer Treatment, Immuno-Oncology, Immunotherapy, News

Jimmy Carter: the New Advocate for Immunotherapy Treatment

Fighting With Immunotherepy
Fighting With Immunotherapy

Being a leader is nothing new for former president Jimmy Carter. Since the end of his political career, he has devoted his time to human rights activism, and his work earned him the 2002 Nobel Peace Prize. Today he has assumed a role he never anticipated: a leader in immunotherapy cancer treatment.

Carter’s diagnosis and treatment

In August 2015, Carter announced that surgery to remove a tumor from his liver had uncovered four spots of melanoma in his brain. He accepted the diagnosis with grace and strength, but that wasn’t the end of the story.

Doctors at Emory University, which is gaining notice as an immuno-oncology center, began treating Carter with pembrolizumab, an immunotherapy drug sold under the brand name Keytruda. The drug, which received Food and Drug Administration approval just over one year ago, does not work directly on the cancer. It works by harnessing the power of the body’s own immune system to destroy the malignant cells.

What does the future hold?

In a more upbeat announcement in early December 2015, Carter revealed that his brain cancer is gone. Since pembrolizumab is so new to the market, there is little long-range data available, so doctors will continue to watch for any signs of recurrence. The tumors have been slow-growing, which is reason for optimism that, should they return, they will not prove fatal.

Our Issels® immuno-oncology center is another leader in alternative cancer treatment. We offer personalized non-toxic therapies in a state-of-the-art facility featuring experienced, caring doctors and staff. Visit our website to learn more about our innovative treatment protocols.

After Cancer, Alternative Cancer Treatment, Cancer Research, Immuno-Oncology, Immunotherapy

Non-Toxic Agent Makes Cancer Cells Glow

Thermal Treatment
Making the Cancer Glow

When you’re looking for small objects in a dark, confined area, your first step is turning on a light. Recent cancer research has uncovered a non-toxic chemical compound with the ability to “turn on the light” that reveals cancer cells.

Breakthrough testing

The study, conducted at Oregon State University, was presented at the annual meeting of the American Association of Pharmaceutical Scientists last October. Researchers injected a substance called silicon napthalocyanine into mice suffering from ovarian tumors. After 24 hours, the chemical had been absorbed by the tumors but was not present in the rest of the body.

Tumors were completely eradicated, and researchers detected no side effects. They are optimistic about the compound working on other types of tumors as well.

“Glow in the dark” cancer cells

Once the compound has been absorbed by a tumor, it causes cancer cells to glow when illuminated with near-infrared light. The effect makes it easier for surgeons to find and remove the cells more effectively, while a chemical reaction combining heat and oxygen kills any remaining cells.

Olena Taratula, lead author of the OSU study, explained that the research demonstrates proof of concept they hope to expand on with further experiments. Next on the researchers’ agenda is developing a system whereby the compound would actually seek out cancer cells. The next round of testing would involve dogs, possibly followed by clinical trials on humans.

Our experienced staff of medical professionals actively works to remain up-to-date on the latest and most innovative cancer research. Contact us to learn why Issels® is a leader in non-toxic integrative immuno-oncology treatments.

Alternative Cancer Treatment, Cancer Research, Immuno-Oncology, Immunotherapy, Uncategorized

Recent Gene Mutation Discovery Linked to Prostate Cancer Offers New Testing and Treatment Hopes

Cancer Support.
Reducing The Chance of Prostate Cancer

We believe at Issels® Immuno-Oncology that integrative immunotherapy treatment plans are critical for successful patient outcomes; which is why we are so excited about the following prostate cancer risk detection and screening news:

The National Cancer Institute estimates that approximately 27,540 American men will die from prostate cancer this year. Yet, as reported in the New England Journal of Medicine, researchers have finally found their first link between inherited genes and prostate cancer — a HOXB13 gene mutation.

The Details

Researchers took samples from 5,100 prostate cancer patients who were 55 years old or younger (94 families represented) and 1,400 healthy men. After sequencing more than 200 genes, they found the following:

  • 72 men in four families carried the same HOXB13 gene mutation.
  • Only one man in the control group had it.

Although these results aren’t definitive proof that the mutation causes prostate cancer, it does appear to be a factor. The researchers also found two more mutations among African men, but they need a larger sampling to confirm if these mutations also play a role.

The Big Picture

Doctors trace the risk of inherited breast cancer in women through tests that look for mutations of BRCA1 and BRCA2 genes that can contribute to cancer growth. The HOXB13 mutation offers hope that doctors might one day be able to test men for genetic links in a similar fashion.

Since men with the HOXB13 gene mutation carry 10-20 times more risk of getting prostate cancer before they reach 55 years old, the discovery of this gene is a scientific breakthrough. At Issels®, we search for breakthroughs like these every single day. Contact us today for more information!

Alternative Cancer Treatment, Cancer Research, Immuno-Oncology, Immunotherapy, Uncategorized

Kidney Cancer Beaten by Innovative Immuno-Oncology Treatments

Preventing Kidney Cancer
Preventing Kidney Cancer

Philip Prichard sought out oncologist Nizar M. Tannir at Houston’s MD Anderson Cancer Center in February 2013 with a massive 8-inch, 3.5 pound tumor and just months to live. Despite a previous surgery and other therapies, Prichard’s renal cell cancer had spread to his liver and lungs.

The last hope?
A clinical trial run by Tannir utilizing immunotherapy – the body’s own immune system – to fight cancer cells. The immune-oncology drugs were hoped to enable Prichard’s immune system, specifically his T-cells, recognize and destroy cancer cells that would have previously escaped detection.

The results?
Two weeks after the first treatment, Prichard’s fever, pain, night sweats, weight loss and anemia were relieved. After eight weeks and four infusions, the tumor shrunk approximately 50-60%. After two years, Prichard is so healthy Tannir must now decide if it’s time to stop Prichard’s treatments.

The immuno-oncology breakthrough?
Highly expensive, but effective drugs including ipilimumab, nivolumab and pembrolizumab that have been approved by the FDA for immuno-oncology. Though they are not a one-size-fits all option, talk at the American Society of Clinical Oncology annual conference in Chicago is expected to be dominated by these immuno­therapies.

The trickle-down effect?
Dozens of studies are now underway seeking to expand on recent successes, and widen the scope of treatable cancers to include bladder, breast, Hodgkin’s lymphoma, head and neck tumors, and more. The immunotherapy drugs are also being tested in varying combinations with each other and other therapies. Early results look promising.

Today, immuno-oncology is being hailed as the fourth pillar of cancer treatment. Are you taking advantage of its miraculous results? Get your hope and your life back – contact Issels® the experienced cancer immunotherapy expert today!